Article: The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
AuthorsLiang, B3
He, ML5
Chan, Cy5
Chen, Yc5
Li, XP1
Li, Y3
Zheng, D4
Lin, MC2
Kung, HF5
Shuai, XT3
Peng, Y3
KeywordsCombined gene therapy
Glioma
In vivo gene transfer
Nonviral vector
PEI PEGylation
Tumor targeting
Issue Date2009
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterials
CitationBiomaterials, 2009, v. 30 n. 23-24, p. 4014-4020 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.biomaterials.2009.04.011
AbstractCombined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.
ISSN0142-9612
2011 Impact Factor: 7.404
2011 SCImago Journal Rankings: 0.633
DOIhttp://dx.doi.org/10.1016/j.biomaterials.2009.04.011
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLiang, B
dc.contributor.authorHe, ML
dc.contributor.authorChan, Cy
dc.contributor.authorChen, Yc
dc.contributor.authorLi, XP
dc.contributor.authorLi, Y
dc.contributor.authorZheng, D
dc.contributor.authorLin, MC
dc.contributor.authorKung, HF
dc.contributor.authorShuai, XT
dc.contributor.authorPeng, Y
dc.date.accessioned2010-09-06T06:19:55Z
dc.date.available2010-09-06T06:19:55Z
dc.date.issued2009
dc.description.abstractCombined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationBiomaterials, 2009, v. 30 n. 23-24, p. 4014-4020 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.biomaterials.2009.04.011
dc.identifier.doihttp://dx.doi.org/10.1016/j.biomaterials.2009.04.011
dc.identifier.epage4020
dc.identifier.hkuros156070
dc.identifier.isiWOS:000267469300023
dc.identifier.issn0142-9612
2011 Impact Factor: 7.404
2011 SCImago Journal Rankings: 0.633
dc.identifier.issue23-24
dc.identifier.openurl
dc.identifier.pmid19427690
dc.identifier.scopuseid_2-s2.0-67349190843
dc.identifier.spage4014
dc.identifier.urihttp://hdl.handle.net/10722/70121
dc.identifier.volume30
dc.languageeng
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterials
dc.publisher.placeNetherlands
dc.relation.ispartofBiomaterials
dc.relation.referencesReferences in Scopus
dc.rightsBiomaterials. Copyright © Elsevier BV.
dc.subjectCombined gene therapy
dc.subjectGlioma
dc.subjectIn vivo gene transfer
dc.subjectNonviral vector
dc.subjectPEI PEGylation
dc.subjectTumor targeting
dc.titleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
dc.typeArticle
Author Affiliations
  1. Nanfang Hospital
  2. The University of Hong Kong
  3. Sun Yat-Sen University
  4. Chinese Academy of Medical Sciences
  5. Chinese University of Hong Kong